U.S. FDA classifies Aurobindo Pharma arm Eugia’s formulation plant as OAI
The U.S. FDA has classified a manufacturing facility belonging to Aurobindo Pharma's subsidiary, Eugia Pharma, as 'Official Action Indicated' (OAI). The company stated that it expects no material impact on its operations or financials following the inspection.
Why it matters
Regulatory actions against pharmaceutical manufacturers can impact supply chains and investor confidence in the global healthcare sector.
Aurobindo Pharma subsidiary Eugia Pharma Specialities’ formulation manufacturing facility near Hyderabad has been classified by the U.S. Food and Drug Administration (U.S. FDA) as “official action indicated” (OAI).
The article provides a factual account of the regulatory classification and the company's response without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in